From bench to bedside: Utilization of an in vitro model to predict potential drug-drug interactions in the kidney: The digoxin-mifepristone example

Journal of Clinical Pharmacology

Volumn 43, Issue 7, 2003, Pages 743-750

  Woodland, Cindy ^a   Koren, Gideon ^b   Ito, Shinya ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b NONE

Author keywords

Cell culture; Digoxin; Drug interaction; MDCK cells; Mifepristone; P glycoprotein; RU486; Vinblastine

Indexed keywords

AMIODARONE; CARDIAC GLYCOSIDE; CLARITHROMYCIN; DIGOXIN; GLYCOPROTEIN P; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; MIFEPRISTONE; PROPAFENONE; QUINIDINE; VERAPAMIL; VINBLASTINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; IN VITRO STUDY; KIDNEY; KIDNEY CELL; KIDNEY TUBULE CELL; NONHUMAN; POLYPHARMACY;

EID: 0038650509     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003254800     Document Type: Article

References (42)

1. Roblin DW, Juhn PI, Preston BJ, Della Penna R, Feitelberg SP, Khoury A, et al: A low-cost approach to prospective identification of high cost outcomes. Med Care 1999;37(11):1155-1163.
2. Kohler GI, Bode-Boder SM, Busse R, Hoopmann M, Welte T, Boger RH: Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Intl J Clin Pharmacol Ther 2000;38(11):504-513.
3. Kelly WN: Potential risks and prevention, part 1: fatal adverse drug events. Am J Health-Syst Pharm 2001;58(14):1317-1324.
4. Pieroni RE, Marshall J: Fatal digoxin-quinidine interaction in an elderly woman. J Am Geriatr Soc 1981;29(9):422-425.
5. Laberge P, Martineau P: Clarithromycin-induced digoxin intoxication. Ann Pharmacother 1997;31(9):999-1002.
6. Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, et al: Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998;64(1):123-128.
7. Xu H, Rashkow A: Clarithromycin-induced digoxin toxicity: a case report and a review of the literature. Conn Med 2001;65(9):527-529.
8. Eichhorn EJ, Gheorghiade M: Digoxin. Prog Cardiovasc Dis 2002; 44(4):251-266.
9. Soldin SJ: Digoxin - issues and controversies. Clin Chem 1986; 32(1):5-12.
10. Steiness E: Renal tubular secretion of digoxin. Circulation 1974; 50:103-107.
11. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, et al: Transport of digoxinby human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 1992;263:840-845.
12. DeLannoy IAM, Silverman M: The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Comm 1992;189:551-557.
13. Ito S, Woodland C, Harper PA, Koren G: P-glycoprotein-mediated renal tubular secretion of digoxin. Life Sci 1993;53:PL25-PL31.
14. Schinkel AH, Wagenaar E, VanDeemter L, Mol CAAM, Borst P: Absence of the mdria P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995;96:1698-1705.
15. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-7738.
16. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 1989;37(2): 159-164.
17. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I: Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987;84:265-269.
18. Arceci RJ, Croop JM, Horowitz SB, Housman D: The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci USA 1988;85(12):4350-4354.
19. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Graver L, Biedler JL, Melamed MR, et al: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain harrier sites. Proc Natl Acad Sci USA 1989;86(2):695-698.
20. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, et al: Organic anion-transporting polypeptide B (OATPB) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001;120:525-533.
21. Ito S, Woodland C, Harper PA, Koren G: The mechanism of the digoxin-verapamil interaction in renal tubular cells (LLC-PK1). Life Sci 1993;53:PL399-PL403.
22. Woodland C, Verjee Z, Giesbrecht E, Koren G, Ito S: The digoxin-propafenone interaction: characterization of a mechanism using renal tubular cell monolayers. J Pharmacol Exp Ther 1997;283:39-45.
23. Ito S, Woodland C, Koren G: Characteristics of itraconazole and ketoconazole inhibition of digoxin transport across renal tubular cells. FASEB J 1995;9:A686.
24. Woodland C, Ito S, Koren G: A model for the prediction of digoxin-drug interactions at the renal tubular cell level. Ther Drug Monit 1998;20:134-138.
25. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, et al: St. John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000;68:598-604.
26. Perloff MD, von Moltke LL, Stormer E, Shader RI, Greenblatt DJ: Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 2001;134(8):1601-1608.
27. Spitz IM, Bardin CW: Mifepristone (RU486) - a modulator of progestin and glucocorticoid action. NEJM 1993;329(6):404-412.
28. Ueda K, Okamura N, Hira M, Tanigawara Y, Saeki T, Kioka N, et al: Human P-glycoprotein transports cortisol, aldosterone, dexamethasone, but not progesterone. J Biol Chem 1992;267:24248-24252.
29. Ford JM, Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990;42(3):155-199.
30. Gruol DJ, Zee MC, Trotter J, Bourgeois S: Reversal of multidrug resistance by RU486. Cancer Res 1994;54:3088-3091.
31. Lecureur V, Fardel O, Guillouzo A: The antiprogestatin drug RU486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett 1994; 355:187-191.
32. Fardel O, Courtois A, Drenou B, Lamy T, Lecureur V, Le Prisé P-Y, et al: Inhibition of P-glycoprotein activity in human leukemic cells by mifepristone. Anti-Cancer Drugs 1996;7:671-677.
33. Ito S, Woodland C, Sarkadi B, Hockmann G, Walker SE, Koren G: Modeling of P-glycoprotein-involved epithelial drug transport in MDCK cells. Am J Physiol 1999;277(Renal Physiology 46):F84-F96.
34. Horio M, Gottesman MM, Handler J: Transepithelial transport of vinblastine by kidney-derived cell lines: application of a new kinetic model to estimate in situ Km of the pump. Biochim Biophys Acta 1990;1027:116-122.
35. Koren G, Woodland C, Ito S: Toxic digoxin-drug interactions: the major role of renal P-glycoprotein. Vet Human Toxicol 1998;40(1):45.
36. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG: Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994;54:357-361.
37. Ito S, Woodland C, Koren G: Modeling of cellular digoxin transport. The Pharmacologist 1997;39(1):114.
38. Pedersen KE, Dorph-Pedersen A, Hvidt S, Klitgaard NA, Nielsen-Kudsk F: Digoxin-verapamil interaction. Clin Pharm Ther 1981; 30(3):311-316.
39. Belz GG, Doering W, Munkes R, Matthews J: Interaction between digoxin and calcium antagonists and antiarrhythmic drugs. Clin Pharmacol Ther 1983;33:410-417.
40. Hedman A, Angelin B, Arvidsson A, Dahlqvist R, Nilsson B: Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. Clin Pharmacol Ther 1990;47:20-26.
41. Cone LA, Himelman RB, Hirschberg JN, Hutcheon JW: Itraconazole-related amaurosis and vomiting due to digoxin toxicity [letter]. West J Med 1996;165:322.
42. Partanen J, Jalavin KM, Neuvonen PJ: Itraconazole increases serum digoxin concentration. Pharmacol Toxicol 1996;79:274-276.